PDF icon Download PDF
Dtsch Med Wochenschr 2001; 126(23): 690-695
DOI: 10.1055/s-2001-14692
CME
© Georg Thieme Verlag Stuttgart · New York

Chronische lymphatische Leukämie - Teil 2: Therapie

Chronic lymphocytic leukemia - Part 2: Treatment M. Hallek1 , B. Schmitt1 , B. Emmerich2 , H. Stein3
  • 1Medizinische Klinik III der Ludwig-Maximilians-Universität München, Großhadern
  • 2Medizinische Klinik der Ludwig-Maximilians-Universität München, Innenstadt
  • 3Institut für Pathologie, Klinikum Benjamin Franklin, Freie Universität Berlin
Further Information

Publication History

Publication Date:
10 October 2002 (online)

Also available ateRef
  Permissions and Reprints
Preview

Die Behandlungsoptionen der chronischen lymphatischen Leukämie (CLL) wurden im letzten Jahrzehnt erheblich erweitert. In diesem Teil sollen zunächst die wesentlichen Bausteine und Neuerungen der Therapie dargestellt werden. Anschließend wird auf die Therapieindikation und -strategie eingegangen.

Literatur

  • 1 American Society of Clinical Oncology . American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.  J Clin Oncol. 1994;  12 2471-2508
    Search in Google Scholar
  • 2 American Society of Clinical Oncology . Update of recommendations for the use of hematopoietic growth factors.  J Clin Oncol. 1996;  14 1957-1960
    Search in Google Scholar
  • 3 Anaissie E J, Kontoyiannis D P, O’Brien S, Kantarjian H, Robertson L, Lerner S, Keating M J. Infections in patients with chronic lymphocytic leukemia treated with fludarabine.  Ann Intern Med. 1998;  129 559-566
    Search in Google Scholar
  • 4 Bergmann L. et al . Fludarabine versus fludarabine plus epirubicin in the treatment of chronic lymphocytic leukemia - preliminary results of a randomized phase III multicenter study.  Ann Oncol. 1999;  10 126 (suppl 3))
    Search in Google Scholar
  • 5 Bosch F, Perales M, Cobo F. et al . Fludarabine, cyclophosphamide and mitoxantrone (FMC) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL) abstr.  Blood. 1997;  90 2360 (Suppl 1))
    Search in Google Scholar
  • 6 Buhmann R, Nolte A. et al . CD40-Activated B-Cell Chronic Lymphocytic Leukemia Cells for Tumor Immunotherapy.  Blood. 1999;  93 1992-2002
    Search in Google Scholar
  • 7 Byrd J C, Rai K R, Sausville E A, Grever M. Old and new therapies in chronic lymphocytic leukemia.  Semin Oncol. 1998;  25 65-74
    Search in Google Scholar
  • 8 Byrd J C, Rai K R, Sausville E A, Grever M R. Old and new therapies in chronic lymphocytic leukemia.  Semin Oncol. 1998;  25 66-74
    Search in Google Scholar
  • 9 Cheson B D. New prospects in the treatment of indolent lymphomas with purine analogues.  Cancer J Sci Am. 1998;  4 S27-36
    Search in Google Scholar
  • 10 Cheson B D. Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation.  Semin Hematol. 1998;  35 14-21
    Search in Google Scholar
  • 11 Cheson B D, Frame J N, Vena D, Quashu N, Sorensen J M. Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.  J Clin Oncol. 1998;  16 2313-2320
    Search in Google Scholar
  • 12 CLL trialists’ collaborative group . Chemotherapeutic options in chronic lymphocytic leukemia.  J Natl Cancer Inst. 1999;  91 861-868
    Search in Google Scholar
  • 13 Cooperative group for the study of Immunoglobulin in chronic lymphocytic leukemia . Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia.  N Engl J Med. 1988;  319 902-907
    Search in Google Scholar
  • 14 Diehl L F, Ketchum L H. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.  Semin Oncol. 1998;  25 80-97
    Search in Google Scholar
  • 15 Dreger P, von Neuhoff N, Sonnen R, Kuse R, Viehmann K, Glass B, Kneba M, Schmitz N. Factors determining feasibility and outcome of autologous stem cell transplantation for CLL (abstr.)  Ann Oncol. 1999;  10 25 (Suppl 3))
    Search in Google Scholar
  • 16 Johnson S, Smith A G, Löffler H. French Cooperative Group on CLL . Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicine, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia.  Lancet. 1996;  347 1432-1438
    Search in Google Scholar
  • 17 Hallek M. et al . GCLLSG. Fludarabine plus cyclophosphamide (FC) and dose-intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL).   Ann Oncol. 1999;  10 67 (Suppl 3))
    Search in Google Scholar
  • 18 Han T. et al . Chlorambucil vs combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia.  Cancer. 1973;  31 502-508
    Search in Google Scholar
  • 19 Hansen M M. Chronic lymphocytic leukaemia.  Scand J Haematol. 1973;  18 283-286 (Suppl))
    Search in Google Scholar
  • 20 Hudson R P, Wilson S L. Hypogammaglobulinemia and chronic lymphatic leukemia.  Cancer. 1960;  13 200-204
    Search in Google Scholar
  • 21 Jaksic B, Brugiatelli M, Krc I. et al . High dose chlorambucil versus Binet’s modified cyclophosphamide, doxorubicin, vincristin, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia.  Cancer. 1997;  79 2107-2114
    Search in Google Scholar
  • 22 Juliusson G, Liliemark J. High complete remission rate 2-chloro-2’-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia.   J Clin Oncol. 1993;  11 679-689
    Search in Google Scholar
  • 23 Kato K, Cantwell M J, Sharma S, Kipps T J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells.  J Clin Invest. 1998;  101 1133-1141
    Search in Google Scholar
  • 24 Keating M J, O’Brien S, Lerner S. et al . Long-term follow up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.  Blood. 1998;  92 1165-1171
    Search in Google Scholar
  • 25 Kipps T, Wierda W G, Woods S, Cantwell M J, Prussak C, Rassenti L Z. Gene therapy of leukemias and lymphomas.  Ann Oncol. 1999;  10 37 (Suppl 3))
    Search in Google Scholar
  • 26 Langenmayer I, Nerl C, Knauf W. et al . Interferon alpha 2b in the treatment of early stage CLL with risk for progression. Results of a randomized multicenter study.  Br J Haematol. 1996;  94 362-369
    Search in Google Scholar
  • 27 Leporrier M, Chevret S, Cazin B. et al . Randomized comparison of fludarabine, CAP and ChOP, in 695 previously untreated stage B and C chronic lymphocytic leukemia (CLL) patients.   Blood. 1997;  90 529a (Suppl 1))
    Search in Google Scholar
  • 28 Mauro F R, Foa R. et al . Clinical characteristics and outcome of young chronic lymphocytic leukemia patients.  Blood. 1999;  94 448-454
    Search in Google Scholar
  • 29 Michallet M, Archimboud E, Bandini G. et al . HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia.  Ann Intern Med. 1996;  124 311-315
    Search in Google Scholar
  • 30 Molica S. Progression and survival studies in early chronic lymphocytic leukemia.  Blood. 1991;  78 895-899
    Search in Google Scholar
  • 31 Morrison V A. The infectious complications of chronic lymphocytic leukemia.  Semin Oncol. 1998;  25 98-106
    Search in Google Scholar
  • 32 O’Brien S. Clinical challenges in chronic lymphocytic leukemia.  Semin Hematol. 1998;  35 22-26
    Search in Google Scholar
  • 33 O’Brien S, del G iglio A, Keating M. Advances in the Biology and Treatment of B-Cell Chronic Lymphocytic Leukemia.  Blood. 1995;  85 307-318
    Search in Google Scholar
  • 34 O’Brien S, Kantarjian H, Beran M. et al . Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL) (abst.).  Blood. 1996;  88 480a (Suppl 1))
    Search in Google Scholar
  • 35 Osterborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leucemia.  J Clin Oncol. 1997;  15 1567-1574
    Search in Google Scholar
  • 36 Rai K R, Peterson B L, Appelbaum F R, Kolitz J, Elias  L, Shepherd L, Hines J, Threatte G A, Larson R A, Cheson B D, Schiffer C A. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.   N Engl Med. 2000;  343 1759-1757
    Search in Google Scholar
  • 37 Robertson L E, O’Brien S. et al . Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia.  Leukemia. 1995;  9 943-945
    Search in Google Scholar
  • 38 Rondelli D. et al . 2-Chlordeoxyadenosine in the treatment of relapsed/refractory chronic lymphocytic disorders.  Eur J Hematol. 1997;  58 46-50
    Search in Google Scholar
  • 39 Sawitsky A, Rai K R, Glidewell O, Silver R T. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia.  Blood. 1977;  50 1049-1059
    Search in Google Scholar
  • 40 Seymour J F. et al . Survival of young patients with chronic lymphocytic leukemia faling fludarabine therapy.  Leuk Lymphoma. 1995;  18 493-496
    Search in Google Scholar
  • 41 Sorensen J M, Vena D A. et al . Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute.  J Clin Oncol. 1997;  15 458-465
    Search in Google Scholar
  • 42 Waselenko J K, Flynn J M, Byrd J C. Stem-cell transplantation in chronic lymphocytic leukemia.  Semin Oncol. 1999;  26 48-61
    Search in Google Scholar
  • 43 Wendtner C -M, Schmitt B, Wilhelm M. et al . Redefining the therapeutic goals in chronic lymphocytic leukemia.  Ann Oncol. 1999;  10 505-509
    Search in Google Scholar
  • 44 Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8).  Blood. 1999;  94 2217-2223
    Search in Google Scholar

Korrespondenz

Prof. Dr. med. Michael Hallek

Medizinische Klinik III Klinikum der Universität München Großhadern

Marchioninistraße 15

81377 München